Growth hormone secretagogues (GHS) are a class of compounds that stimulate the pituitary gland’s own GH release, rather than introducing exogenous GH. Three of the most-studied in this class are Ipamorelin, CJC-1295, and GHRP-6. This is a research overview of their mechanisms and published evidence.
The GH Axis — Quick Background
GH release is regulated by two primary hypothalamic hormones: Growth Hormone-Releasing Hormone (GHRH), which stimulates GH release, and somatostatin, which inhibits it. A third pathway involves ghrelin and its receptor (GHSR-1a). Secretagogue peptides typically work through one or both of these pathways.
GHRP-6
GHRP-6 (Growth Hormone Releasing Peptide-6) is a hexapeptide and one of the earliest-studied synthetic GH secretagogues. It acts primarily at the GHSR-1a (ghrelin receptor).
Published Findings
- Demonstrated GH pulse stimulation in multiple human studies from the 1980s-90s during receptor characterization research
- Notable side effect: strong hunger stimulation (ghrelin pathway activation — ghrelin is sometimes called the “hunger hormone”). Published studies consistently report this.
- Some published data suggests anti-inflammatory properties and GI tissue protective effects, though this is less characterized than the GH secretagogue mechanism
Ipamorelin
Ipamorelin is a pentapeptide GH secretagogue and one of the most selective in the class. It acts at GHSR-1a but with significantly reduced effects on cortisol and prolactin compared to earlier GHRPs like GHRP-6.
Published Findings
- 1998 study in European Journal of Endocrinology demonstrated GH release in rats with minimal effects on ACTH, cortisol, or prolactin — establishing the selectivity profile that makes Ipamorelin a cleaner research tool
- Subsequent rodent studies on bone density, body composition changes with GH axis manipulation
- Human data: limited but some pharmacokinetic and safety data from early clinical development by Novo Nordisk (Ipamorelin was investigated as a clinical candidate before being discontinued)
The selectivity argument: because Ipamorelin doesn’t strongly stimulate cortisol or prolactin, it’s considered a cleaner model for studying isolated GH axis effects in research settings.
CJC-1295
CJC-1295 is a GHRH analogue — it acts at the GHRH receptor, not the ghrelin receptor, making it mechanistically distinct from GHRPs. The most common research form uses a Drug Affinity Complex (DAC) technology that extends half-life by binding to albumin.
Published Findings
- 2006 paper in Journal of Clinical Endocrinology & Metabolism showed CJC-1295 DAC produced sustained GH elevation in healthy adults with twice-weekly dosing — a notable pharmacokinetic result for a GHRH analogue
- IGF-1 elevations observed alongside GH increases, as expected given the GH axis pathway
- No significant adverse events in the published trial populations
Ipamorelin + CJC-1295: The Combination Rationale
These two peptides are frequently discussed together in research contexts because they work through complementary pathways: CJC-1295 activates the GHRH receptor, while Ipamorelin activates GHSR-1a. The hypothesis is that simultaneous activation of both pathways produces a more robust and physiologically-timed GH pulse than either alone.
This is supported by the published physiology of GH regulation — endogenous GH pulses involve both GHRH and ghrelin signaling. Published combination data in rodents supports synergistic GH release. Direct human combination trial data is limited.
CJC-1295: “With DAC” vs. “Without DAC” Is Not a Minor Detail
A frequent point of confusion in this space: “CJC-1295” is sold in two meaningfully different forms, and conflating them leads to significant misunderstanding of dosing frequency and duration of action. CJC-1295 with DAC (Drug Affinity Complex) is chemically modified to bind reversibly to albumin in the bloodstream, extending its half-life to several days and enabling infrequent (sometimes once-weekly) dosing schedules studied in some research protocols. CJC-1295 without DAC is chemically identical to a modified GHRH analog (essentially the same core compound as tesamorelin’s parent structure) but lacks the albumin-binding modification, giving it a much shorter half-life of roughly 30 minutes, requiring much more frequent dosing to maintain the intended pulsatile GH-release pattern. These are pharmacologically distinct products despite sharing a name, and published research findings, dosing schedules, and safety data for one do not automatically transfer to the other — checking which specific form a given source is discussing is a necessary first step before drawing any conclusions.
GHRP-6’s Distinctive Side Effect: Pronounced Appetite Stimulation
Among the GH secretagogues, GHRP-6 is particularly notable in the research and community literature for producing a strong appetite-stimulating effect, a consequence of its activity at the ghrelin receptor (GHSR-1a) — ghrelin is, after all, the body’s primary “hunger hormone,” and GHRP-6 was among the first synthetic compounds shown to activate this same receptor pathway. This is mechanistically distinct from Ipamorelin, which is more selective for GH release with comparatively less appetite-stimulating effect at the ghrelin receptor despite acting on the same general receptor family — a selectivity difference that is one of the more practically significant distinctions between these two GHRP-family compounds for anyone considering their differing side-effect profiles.
Frequently Asked Questions
Is CJC-1295 “with DAC” the same product as CJC-1295 “without DAC”?
No — they differ substantially in half-life (days vs. roughly 30 minutes) and therefore in appropriate dosing frequency; findings and protocols for one should not be assumed to apply to the other.
Why does GHRP-6 cause more hunger than Ipamorelin?
Both act on the ghrelin receptor (GHSR-1a), but Ipamorelin is more selective for GH release specifically, while GHRP-6’s activity profile produces a comparatively stronger appetite-stimulating effect at that same receptor — a real, frequently reported distinction between the two compounds.
Is “CJC-1295 without DAC” the same molecule as tesamorelin?
They’re closely related modified GHRH analogs but are not identical — tesamorelin is a distinct, FDA-approved compound (for HIV-associated lipodystrophy) with its own specific structure and approval history, while “CJC-1295 without DAC” is a separate RUO research compound; the similarity is structural family, not molecular identity.
For research education only. GH axis peptides require prescription in most jurisdictions and are not approved OTC compounds. Not medical advice.
